

Another FDA approval in Aurobindo's kitty

18 December 2015 | News | By BioSpectrum Bureau

Another FDA approval in Aurobindo's kitty

Aurobindo Pharma has received final approval from the US Food and Drug Administration (US FDA) to manufacture and market Methylprednisolone Sodium Succinate Injection USP, 40 mg/vial, 125 mg/vial, 500 mg/vial, and 2 g/vial.

The approved ANDA is bioequivalent and therapeutically equivalent to the reference listed drug product (RLD) Solu-Medrol, of Pharmacia and Upjohn.

Methylprednisolone Sodium Succinate Injection is a lyophilized product used in the treatment of various medical conditions viz allergic states, disorders etc. The approved product has an estimated market size of \$102 million for the twelve months ending October 2015, according to IMS.